X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6%
Fri, 1 Feb

AJANTA PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

AJANTA PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m5,8715,4414,851-10.8%-17.4%
Other incomeRs m15215244-71.1%-70.9%
TurnoverRs m6,0225,5944,895-12.5%-18.7%
ExpensesRs m3,8963,7793,7780.0%-3.0%
Gross profitRs m1,9751,6621,073-35.4%-45.7%
DepreciationRs m1501751876.7%24.6%
InterestRs m111-30.8%-35.7%
Profit before taxRs m1,9751,638930-43.3%-52.9%
TaxRs m501385261-32.2%-47.9%
Profit after taxRs m1,4751,254669-46.6%-54.6%
Gross profit margin%33.630.522.1
Effective tax rate%25.323.528.0
Net profit margin%24.522.413.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 17.4% on a year-on-year (YoY) basis. The expenses were down by 3.0% YoY during the same period.
  • The company's operating profit declined by 45.7% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 22.1% in 3QFY19 as against 33.6% in 3QFY18.
  • Depreciation charges increased by 24.6% and finance costs declined by 35.7% YoY, respectively.
  • Other income declined by 70.9% YoY during the quarter.
  • Net profit for the quarter declined by 54.6% YoY. Net profit margins during the quarter declined from 24.5% in 3QFY18 to 13.7% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 10.8% on a quarter-on-quarter (QoQ) basis. The expenses were down by 0.0% QoQ during the same period.
  • The company's operating profit declined by 35.4% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 22.1% in 3QFY19 as against 30.5% in 2QFY18.
  • Net profit for the quarter declined by 46.6% QoQ, while net profit margins declined from 22.4% in 2QFY18 to 13.7% in 3QFY19.

To see how AJANTA PHARMA has performed over the last eight quarters, please visit here.

AJANTA PHARMA Share Price Performance

Over the last one year, AJANTA PHARMA share price has moved up from Rs 1,408.5 to Rs 992.3, registering a Loss of Rs 416.3 or around 29.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,916.8 (up 0.3%). Over the last one year it has moved down from 14,358.7 to 13,916.8, a gain of 442 points (down 3.1%).

Overall, the S&P BSE SENSEX is up 1.2% over the year.

Current Valuations

At the current price of Rs 992.3, the price to earnings (P/E) ratio of AJANTA PHARMA stands at 22.2 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 4.3 times.

Equitymaster requests your view! Post a comment on "AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6%". Click here!

  

Related Views on News

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 17, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - MYLAN COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS